Expand ELDN Menu
ELDN MENU

ELDN Latest Press Releases

-- March 19, 2026 --

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results Globe Newswire 5:10 PM

-- March 16, 2026 --

Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine Globe Newswire 7:00 AM

-- March 10, 2026 --

Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation Globe Newswire 7:00 AM

-- March 9, 2026 --

NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes PRNewswire 7:00 AM

-- March 4, 2026 --

Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference Globe Newswire 4:05 PM

-- February 5, 2026 --

Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 Globe Newswire 4:10 PM

-- January 23, 2026 --

Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium Globe Newswire 7:00 AM

-- January 8, 2026 --

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook Globe Newswire 4:05 PM

-- December 1, 2025 --

Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference Globe Newswire 7:00 AM

-- November 18, 2025 --

Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine Globe Newswire 4:05 PM
Market Data Delayed 15 Minutes